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Abstract: Bone scintigraphy is key in imaging skeletal metastases in newly diagnosed prostate cancer.
Unfortunately, a notable proportion of scans are not readily classified as positive or negative but
deemed indeterminate. The extent of reporting of indeterminate bone scans and how such scans
are handled in clinical trials are not known. A systematic review was conducted using electronic
databases up to October 2016. The main outcome of interest was the reporting of indeterminate
bone scans, analyses of how such scans were managed, and exploratory analyses of the association
of study characteristics and the reporting of indeterminate bone scan results. Seventy-four eligible
clinical trials were identified. The trials were mostly retrospective (85%), observational (95%), large
trials (median 195 patients) from five continents published over four decades. The majority of studies
had university affiliation (72%), and an author with imaging background (685). Forty-five studies
(61%) reported an indeterminate option for the bone scan and 23 studies reported the proportion of
indeterminate scans (median 11.4%). Most trials (44/45, 98%) reported how to handle indeterminate
scans. Most trials (n = 39) used add-on supplementary imaging, follow-up bone scans, or both.
Exploratory analyses showed a significant association of reporting of indeterminate results and
number of patients in the study (p = 0.024) but failed to reach statistical significance with other
variables tested. Indeterminate bone scan for staging of prostate cancer was insufficiently reported in
clinical trials. In the case of indeterminate scans, most studies provided adequate measures to obtain
the final status of the patients.
Keywords: bone neoplasms; classification; diagnosis; prostatic neoplasms; radionuclide imaging
1. Introduction
Bone scintigraphy (BS) has been the method of choice for staging of skeletal metastases in newly
diagnosed prostate cancer for decades, and planar BS continues to be the recommended method across
all clinical urological guidelines [1–3]. The outcome of BS may in many cases determine the treatment
decision of the patients.
The conclusion from a BS may not always be definitive. In large studies, the proportion of
indeterminate scans can amount to 16–26% [4,5]. Bone scans are not specific for metastasis but
reflect bone remodeling of any cause. Thus, an imaging avid lesion may not per se represent skeletal
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metastasis. The diagnostic characteristics of planar BS show sensitivity and specificity of approximately
85% and 75–80% [6–8].
When clinicians receive imaging results for their patients, they must rely on interpretation by
imaging experts. A notable proportion of indeterminate BS results have been reported in large studies
with consecutive recruitment [4,5]. The reporting of indeterminate scan results in clinical trials in
general remains unclear. However, indeterminate cases are rarely reported in diagnostic test accuracy
studies [9]. In clinical practice, handling of patients with indeterminate imaging results can vary widely.
Some clinicians may decide to do supplementary imaging on all patients with inconclusive results;
others do so very infrequently [4,10]. The reporting of indeterminate imaging findings, and how to
deal with them, has not previously been described in cancer imaging.
The purpose of this systematic review was to analyze the extent of reporting of indeterminate BS
results in the staging of newly diagnosed prostate cancer, and to explore the extent and methods of
supplementary or follow-up imaging to reach a final conclusion. Finally, we tried to identify if any
study characteristics were associated with reporting of indeterminate BS results.
2. Materials and Methods
2.1. Literature Search Strategy
A comprehensive literature search was performed using four different bibliographic databases,
MEDLINE (Ovid Technologies, New York, NY, USA), Embase (Ovid Technologies, New York,
NY, USA), Web of Science (Clarivate Analytics, Philadelphia, PA, USA), and The Cochrane Library
(http://www.cochranelibrary.com). The search period span from the start of each database until
6 October 2016. The search was customized for each database using both controlled thesaurus terms
and natural language terms for synonyms (Supplementary material, Table S1). All original references
were imported into the reference managing tool RefWorks (Proquest, Ann Arbor, MI, USA) where
duplicate references were manually deleted. The references were then imported into the screening and
data extraction software Covidence and were evaluated for inclusion in the review.
2.2. Eligibility Criteria
According to the PICOS concept (patient, intervention, comparator, outcome, study type),
the following eligibility criteria were used. (1) Prostate cancer patients; (2) stage: newly diagnosed;
(3) the use of planar bone scintigraphy for the detection of skeletal metastases; (4) no requirements
for any comparator; (5) reporting of the original bone scan results (i.e., no registry trials);
(6) any study design; (7) a minimum of 20 patients per study. In papers with mixed types of cancers,
settings, imaging methods, etc., data should be extractable in accordance with the seven eligibility
criteria. At first, all papers were reviewed for eligibility by reading the title and abstract. Papers not
rejected based on title/abstract were retrieved for full text reading. Two independent readers
performed the selection and subsequent extraction process. The protocol for this review was not
registered in a public database. The systematic review was performed in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline [11].
2.3. Reporting of Bone Scan Results
Each paper was reviewed for the reporting of bone scan results (dichotomous outcome versus
non-dichotomous outcome). Papers with non-dichotomous outcome were classified by their way of
reporting the bone scan and any use of additional imaging (e.g., computed tomography or magnetic
resonance imaging) used to clarify indeterminate bone scan results.
2.4. Epidemiological and Methodological Analyses of the Eligible Studies
We extracted information about study design (interventional or non-interventional), patient
enrollment (prospective versus retrospective), selection of patients (consecutive or non-consecutive
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enrolment), number of included patients, affiliation to university or university hospital, affiliation to an
imaging department, number of authors, geographical region, publication year, journal name, impact
factor (Thomson Reuters, 2016 if not mentioned otherwise), indexation in MEDLINE, and research
domain. The assessment of trial methodology was based on the actual reporting in the original
papers. This implied that an item was classified as absent is not specifically reported in the paper.
By example, a trial was classified as a prospective trial only if the word ‘prospective’ was mentioned,
the terminology was clear (e.g., “we enrolled”) or the trial was classified as an interventional trial.
All trials were classified as observational unless the trial was reported as experimental or interventional,
or it was a randomized or diagnostic test accuracy study (cross-sectional cohort) with appropriate
ethical approval. Finally, unbiased recruitment of patients was acknowledged only if the phrase
“consecutive” or “unselected” was used or it was clear that a trial included all patients or an unbiased
selection of patients examined in a well-defined period and the eligibility criteria were specified.
In the case of diverging options, e.g., a study included both retrospective and prospectively recruited
patients [12] the largest sample determined the study methodology classification. We did not look for
duplicate reporting of data even though some trials appear to use data from the same population for
separate purposes [13,14].
2.5. Statistics
Descriptive statistics included calculation of median and range. Fisher’s exact test was used for
analysis of reporting or not of indeterminate bone scan results with all variables. In cases of a suspect
trend, e.g., number of authors, year of publication, and impact factor, we used logistic regression.
2.6. Approvals
The study did not contain individual data but summary data from previously published papers.
There are no requirements for ethical approval or informed consent according to national legislation.
3. Results
3.1. Literature Search and Study Demographics
The systematic literature search identified 349 individual publications from four databases, which
was reduced to 215 papers after removal of duplicates (Figure 1). A total of 114 papers were rejected
based on title and abstract, and 101 reports were available for full-text reading. One report was not
achievable in full text, 26 papers were found ineligible, thus resulting in 74 papers for data extraction
(Figure 1) (Supplementary material, Table S2). The study demographics showed a span of four decades
of research, with a median year of publication of 2003; most papers were published in urological
papers followed by imaging and oncology journals (Table 1). Half of the papers originated from
Europe, but the regional distribution covered five continents. The vast majority of papers originated
from university departments, and had at least one author with affiliation to an imaging department.
The majority of the trials were retrospective and observational; unbiased recruitment was ensured on
approximately 60 percent of the trials.
3.2. Reporting of Indeterminate Bone Scan Results
Forty-five (60.8%) of the papers reported an option for the BS to be inconclusive. A three-level
disease classification (positive, negative, indeterminate) was used in 40 trials, where five trials classified
the BS results on a scale from four to seven options. Twenty-three of the 45 papers reported the number
of patients with indeterminate scan results. The median proportion of such results was 11.4% (range
0.2–28.5%). The vast majority of these studies reported how they handled indeterminate scan results
(44 of 45 studies, Table 2). Most trials (n = 39) used add-on supplementary imaging; follow up bone
scans, or both, whereas three studies declared indeterminate BS as negative for skeletal metastasis,
and one study used a consensus reading of the BS by multiple readers. One diagnostic test accuracy
Diagnostics 2018, 8, 9 4 of 11
study handled indeterminate bone scans as negative and positive (sensitivity analysis) for calculation
of diagnostic characteristics of BS [15]. The supplementary imaging was computed tomography (CT) or
magnetic resonance imaging (MRI) in most cases, whereas X-ray was used alone or in combination with
CT/MRI in 13 studies. A few studies used single photon emission computed tomography (SPECT),
SPECT/CT or did not specify the applied methodologies. The results of supplementary follow-up
imaging are seldom reported and thus not part of the scope of this paper.
Twenty-nine (29/74, 39.2%) of the papers reported the BS reading solely with a dichotomous
outcome as negative or positive for skeletal metastases. In five cases, the authors stated that positive
and/or negative BS results were confirmed by supplementary imaging, either for all cases [16–18] or
selected cases [19,20].
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Table 1. Study demographics of the 74 included papers.
Variable Data
Reporting of equivocal BS results, n (%)
Yes 45 (60.8%)
No 29 (39.2%)
Year of publication, median (range) 2003 (1974–2016)
Number of patients, median (range) 195 (25–1515)















Geographical origin, n (%)
Europe 37 (50.0%)
Asia 22 (29.7%)
North America 11 (14.9%)
Middle East 3 (4.1%)
Africa 1 (1.4%)
University affiliation, n (%)
Yes 53 (71.6%)
No 21 (28.4%)
Imaging affiliation, n (%)
Yes 50 (67.6%)
No 24 (32.4%)
Impact factor, n (%)
Journals without impact factor 5 (6.8%)
Journals with impact factor 69 (93.2%)
Impact factor, median (range) 2.309 (0.815–33.405)
MEDLINE indexation, n (%)
Yes 70 (94.6%)
No 4 (5.4)
Abbreviations: BS, bone scintigraphy.
Table 2. Handling of equivocal bone scan results.
Variable Data
Reporting of equivocal BS results, n 45
Described handling of equivocal results, n (%)
Yes 44 (97.8%)
No 1 (2.2%)
Supplementary imaging only, n 36
Type of supplementary imaging and/or management
X-ray 9
CT or MRI 21
X-ray and/or CT/MRI 4
Other 2
Supplementary imaging and follow up bone scans, n 2
Follow up bone scans only, n 1
Equivocal bone scans considered negative for skeletal
metastases, n
3
Sensitivity analysis, n 1
Third party arbitrator of equivocal bone scans, n 1
Abbreviations: BS, bone scintigraphy; CT, computed tomography, MRI, magnetic resonance imaging.
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3.3. Association of Research Methodology and BS Reporting
We performed exploratory statistical analysis to analyze if certain study characteristics were
associated with reporting of indeterminate bone scan results. The results of variables on an ordinal
scale showed a statistically significant trend for reporting of indeterminate results with the number
of patients in the study (p = 0.024, Figure 2a), but not significant differences for year of publication
(p = 0.423, Figure 2b), impact factor (0.686, Figure 2c), or number of authors (p = 0.835, Figure 2d).
None of the dichotomous variables showed any significant differences (Table 3). Numerically assesses,
reporting of indeterminate BS results was observed in journals with high impact factor (Figure 2c),
whereas lack of reporting of indeterminate results was apparent in oncology journals, reports from
Asia, oncology journals, and studies with non-consecutive patients (Table 3). There were no apparent
differences among papers with or without university affiliation, imaging affiliation, study design,
and MEDLINE indexation.
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Table 3. Study design and reporting of equivocal scan results. 
Variable Numbers Eq Not Reported (%) Eq Reported (%) p-Value 
Geographical origin    0.128 
Europe 37 35.1 64.9  
Asia 22 59.1 40.9  
North America 11 18.2 81.8  
Middle East 3 33.3 66.7  
Africa 1 0.0 100.0  
Research domain    0.190 
Urology 36 33.3 66.7  
Imaging 18 33.3 66.7  
Oncology 16 62.5 37.5  
Other 4 25.6 75.0  
Figure 2. The association of variables with reporting of equivocal bone scans. There was a statistically
significant trend with the number of patients in the trials with number of patients in each trial (a);
but not with the year of publication (b); the impact factor of the journals (c) or the number of authors (d).
Reporting of equivocal is shown with open bars, no equivocal scans with closed bars.
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Table 3. Study design and reporting of equivocal scan results.
Variable Numbers Eq Not Reported (%) Eq Reported (%) p-Value
Geographical origin 0.128
Europe 37 35.1 64.9
Asia 22 59.1 40.9
North America 11 18.2 81.8
Middle East 3 33.3 66.7
Africa 1 0.0 100.0
Research domain 0.190
Urology 36 33.3 66.7
Imaging 18 33.3 66.7
Oncology 16 62.5 37.5
Other 4 25.6 75.0
University affiliation, n (%) 0.603
Yes 53 41.5 58.5
No 21 33.3 66.7
Imaging affiliation, n (%) 0.803
Yes 50 38.0 62.0
No 24 41.7 58.3
Study design 0.642
Experimental 4 50.0 50.0
Observational 70 38.6 61.4
Patient enrollment 1.000
Prospective 11 36.4 63.6
Retrospective 63 39.7 60.3
Consecutive patients 0.092
Yes 45 31.1 68.9
No 29 51.7 48.3
MEDLINE indexation 0.642
Yes 70 38.6 61.4
No 4 50.0 50.0
4. Discussion
Clinicians require definite answers from imaging of their patients, but some lesions are difficult
to interpret. Setting a stage where imaging results can only be classified as positive or negative does
not represent the clinical reality in imaging. This has been documented with BS in large clinical
trials [4,5]. How this dilemma is solved in clinical practice remains to be documented. This paper
described, to the best of our knowledge, the first public available review of the reporting and handling
of indeterminate bone scan results among a very large sample of clinical trials. The study showed a
lack of methodological rigor for proper classification of the uncertainty with bone scan results in a
large proportion of the studies.
The reporting of indeterminate trials in oncology has not been described. However, in diagnostic
test accuracy trials in general, the issue is well established. A recent report identified 1156 original
diagnostic papers in 22 systematic reviews and showed reporting of uninterpretable, indeterminate,
and missing results in only 35% of the reports [9]. The findings by Shinkins et al. [9] and the present
data are somewhat compatible; even though approximately 60% of the trials reported an indeterminate
option for BS, only 23 studies (31%) actually showed data for indeterminate BS results. Still, we mainly
aimed to identify indeterminate options for the bone scan; we did not look for uninterpretable or
missing data. Finally, we are well aware that clinical trials, published in clinical journals, as with
most of the references presented in this systematic review, are different in research methodology from
diagnostic test accuracy studies, with the primary focus on the validity of the index test. However,
methodological errors in the reporting of indeterminate trial results are present in both diagnostic test
accuracy trials and clinical trials where the reference test is a dichotomous outcome, bone metastases
present or absent.
Diagnostics 2018, 8, 9 8 of 11
Planar bone scans are widely recommended across urological guidelines for the staging of
newly diagnosed prostate cancer [1–3]. Technical developments in form of single photon emission
tomography/computer tomography (SPECT/CT) have shown to improve specificity over planar
bone scans [21,22]. Imaging experts may argue that planar BS is obsolete in the presence of
SPECT/CT. However, urological guidelines do not see it that way. Except for the latest version
of the prostate guideline from National Comprehensive Cancer Network, no clinical guidelines
even mention SPECT/CT. In addition, whole body SPECT/CT is often used as an add-on to
indeterminate planar bone scans, not as the method of choice per se [10,21,23]. A multitude of
imaging modalities has evolved, including positron emission tomography (PET)/CT with various
tracers and diffusion-weighted magnetic resonance imaging (DW-MRI). There are no overviews of the
reporting of indeterminate of scans on a patient or lesion level with these methodologies. Indeterminate
results are seldom mentioned in diagnostic trials for bone metastases with PET/CT in prostate, but
when it occurred, indeterminate lesions may occur in more than 17% of the cases [24].
The vast majority of studies reporting on indeterminate bone scan results presented data for the
attempts to get a final diagnosis. Most studies used supplementary anatomical imaging, e.g., targeted
X-ray, CT, and/or MRI. The validity and complexity of the examinations, which follow the BS, to
obtain a clinical relevant bone status were not examined in detail here. This follow = up is clinical
relevant for individual patients, but of minor importance for the validity of the BS as an index test in
staging of patients in general.
In an attempt to identify reports with proper reporting of unclear imaging findings, we performed
analyses of study characteristics. Besides the size of the trial, no variable was statistically associated
with such reporting. Reporting of indeterminate results was observed in journals with a high impact
factor, whereas lack of reporting of indeterminate results was apparent in oncology journals, reports
from Asia, and studies with non-consecutive patients.
The median proportion of indeterminate scan results, among those 23 papers reporting such
details, was 11%. This figure is notably lower than the 16–26% reported previously [4,5]. It should,
however, be noted, that a large proportion of the included studies were retrospective trials,
and enrollment of consecutive patients was noted in only approximately 60% of the trials. The results
remain speculative if patients with inconclusive imaging findings have been removed from the study
population. Such considerations are highly relevant for societies and authorities that use clinical trial
results for guidelines and treatment algorithms. Strict research methodology is usually confined to
randomized controlled trials and diagnostic test accuracy studies, e.g., The Standards for Reporting
of Diagnostic Accuracy Studies (STARD), which describe the reporting criteria for diagnostic test
accuracy studies [25]. The initial STARD checklist from 2003 required disclosure of how indeterminate
(as well as missing) index tests were handled.
This study comprised studies with BS. Still, the underlying research methodological issue of how
to handle unclear study results is general. Unclear imaging findings are not restricted to bone scans;
there are a plenitude of other examples, e.g., in renal and adrenal mass imaging [26,27], pulmonary
perfusion imaging [28], and brain imaging [29]. The topic of missing or indeterminate results of
diagnostic testing has been debated for a long time in other areas of medicine besides imaging [30–32].
Even though planar bone scans may be replaced by more accurate imaging methods,
indeterminate imaging results may still occur. Imaging experts as well as clinicians may be aware of
the situation that some investigations may be inconclusive. Based on pre-existing risk factors and the
localization and extent of lesions, the imaging expert should guide the clinicians on the requirement
for any supplementary imaging, including the choice of appropriate methods. Complicated cases may
be discussed at multi-disciplinary team conferences. Such a recommendation is valid for planar bone
scans as well as other modalities.
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5. Conclusions
Reporting and analysis of indeterminate imaging results were inadequately handled in staging
for bone metastases in prostate cancer. We encourage imaging experts to abstain from a dichotomous
classification if such is not obvious. In any imaging study, the authors should adhere to, and editors require
compliance with, relevant sections of the STARD recommendations for reporting of diagnostic studies.
Supplementary Materials: The following are available online at www.mdpi.com/2075-4418/08/1/9/s1.
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